Bridged polycyclic compound based compositions for controlling cholesterol levels

Abstract

A pharmaceutically active agent, a pharmaceutically active agent carrier and method of use thereof are described. In some embodiments, a system may include a composition. The composition may include one or more bridged polycyclic compounds. At least one of the bridged polycyclic compounds may include at least two cyclic groups, and at least two pharmaceutically active agents may be associated with the bridged polycyclic compound. In some embodiments, one or more bridged polycyclic compounds may be administered to a subject to improve cardiac and / or cardiovascular health. In some embodiments, one or more bridged polycyclic compounds may be administered to a subject to control cholesterol levels.

Description

PRIORITY CLAIM[0001]This application claims priority to U.S. Provisional Patent Application No. 61 / 074,475 entitled “BRIDGED POLYCYCLIC COMPOUND BASED COMPOSITIONS FOR CONTROLLING CHOLESTEROL LEVELS” filed on Jun. 20, 2008, which is incorporated by reference herein.BACKGROUND OF THE INVENTION[0002]1. Field of the Invention[0003]The present disclosure generally relates to bridged polycyclic based compounds for the inhibition and amelioration of disease. More particularly, the disclosure generally relates to systems and methods for formulating antiviral, antibacterial, antifungal, antidisease compositions using these bridged polycyclic based compounds.[0004]2. Description of the Relevant Art[0005]Dendrimers are branched polymers with densely packed end-functional groups that can be used to attach the dendrimers to bioactive molecules such as drugs, targeting ligands and imaging agents. Since a significant portion of a dose of pharmaceutical drugs is lost in the circulation due to impa...

AI Technical Summary

Benefits of technology

[0015]Embodiments of the present invention address the problems described above by providing novel compositions and methods for altering cholesterol levels, altering triglyceride levels, reducing weight, and / or suppressing hunger. The present invention solves the problems described above by providing novel compositions and methods for reducing and / or ameliorating maladies associated with high LDL, cholesterol and or lipids in general. Embodiments of the present invention provide unique methods and compositions that are safe and effective for regular use by both humans and animals.

[0060]In some embodiments, an oral surface may be coated with a coating. The coating may include a chemical composition at least a portion of which forms an antimicrobial coating over at least a portion of the oral surface. The coating may include a chemical composition at least a portion of which forms an anti-inflammatory coating over at least a portion of the oral surface. The coating may include a chemical composition at least a portion of which decreases bleeding over at least a portion of the oral surface. The coating may include a chemical composition at least a portion of which decreases inflammation over at least a portion of the oral surface.

[0061]In some embodiments, a composition may include bridged polycyclic compounds. Bridged polycyclic compounds may include cholesterol controlling (e.g., reducing) pharmaceutically active agents (e.g., nicotinic acid derivatives, niacin derivatives). The composition may be used to form a coating in at least a portion of an oral cavity. The coating may function to release pharmaceutically active agents slowly over time as the coating dissolves. As the coating dissolves the pharmaceutically active agents may be released reducing cholesterol. Slowly releasing certain pharmaceutically active agents may reduce some side effects (e.g., flushing associated with nicotinic acid). In some embodiments, slow release of pharmaceutically active agents may allow agents to be administered in a controlled manner for subjects (including humans and / or animals) who refuse to or for other reasons are not capable of taking their medicine in a more traditional manner.

Problems solved by technology

Since a significant portion of a dose of pharmaceutical drugs is lost in the circulation due to impaired uptake by the cells especially in the case of drug resistant cells.

However, there are problems associated with using dendrimers, especially when scaling up production to commercial quantities.

These two methods both suffer from major problems when it comes to practical synthesis, in particular, the necessity for repeated and time-consuming purifications.

Additional problems associated with the synthesis of dendrimers include: defects in the molecular structure; and the crowded molecular structure of dendrimers.

The molecular structure of dendrimers is typically so crowded that many times other molecules become trapped within the spaces within the molecular structure of the dendrimer.

Inhibition of gastrointestinal lipase results in unabsorbed fat is excreted in the feces.

Images